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Summary
Background: Oxaliplatin (L-OHP) is a platinum complex that
possesses activity against human and murine cells in vitro
and in vivo, including colorectal carcinoma-derived cell lines,
and cells that have been selected for resistance to cisplatin.
We report two consecutive phase II trials of L-OHP for treat-
ment of patients with advanced colorectal carcinoma.
Patients and methods: Fifty-eight patients were entered in
study I, and 51 patients in study II. All of the patients had
tumor progression when they were treated, prior to their
enrolment, with a fluoropyrimidine-containing regimen. In
both trials treatment consisted of L-OHP, 130 mg/m2, by i.v.
infusion for two hours; the treatment was repeated every 21
days.
Results: Response to therapy: Study I: Fifty-five patients
were assessed for response. The response rate was 11% (95%
CI, 0.03-0.19). Study II: All 51 patients were assessed for
response. The response rate was 10% (95% CI, 0.017-0.18).
The overall response rate for the 106 evaluated patients was
10% (95% CI, 0.046-0.16). Times to disease progression in
responders were 4, 4, 4.5+, 5, 5, 6, 6, 6, 6+, 9, and 13
months. The dose-limiting toxic effect was sensory peripheral
neuropathy. The incidence of severe peripheral neuropathy
grades was: Study I: grade 3, 23% of patients, and grade 4,
8% of patients. Study II: grade 3,14% of patients, and grade
4, 4% of patients. Severe neuropathy had a favorable course
in all of the patients who had long-term neurologic follow-up.
Diarrhea and myeloid impairment were minor.
Conclusion: L-OHP produced modest, but definite anti-
tumor activity in patients with advanced colorectal carci-
noma who were previously resistant to chemotherapy includ-
ing fluoropyrimidines. Toxicity is within acceptable limits of
tolerance at the dose and schedule of oxaliplatin used in this
trial.
Key words: advanced colorectal carcinoma, oxaliplatin,
phase II study
Introduction
Oxaliplatin [trans-L-l,2-diaminocyclohexane] oxalato-
platinum (II), (L-OHP) is a platinum complex with an
oxalato ligand as leaving group and a 1,2-diamino-
cyclohexane (dach) carrier [1, 2]. The drug exerts anti-
tumor activity against a number of human and murine
tumor cells in vitro and in vivo, including colorectal
cancer-derived cell lines [1-4]. It possesses a higher
cytotoxic potency on a molar basis than do cisplatin
and paraplatin [3], and it is active on various cell lines
that have been selected for resistance to cisplatin [3,4],
Preliminary studies have suggested that combination
therapy with 5-fluorouradl (5-FU) and L-OHP is syn-
ergjstic against L1210 leukemia transplanted into mice
PI-
Toxic effects of oxaliplatin include peripheral neuro-
pathy, vomiting, diarrhea, and mild myelosuppression.
The drug has no renal toxicity [2, 5]. L-OHP given at
a circadian rhythm-modulated i.v. infusion rate to
patients with advanced colorectal carcinoma yielded
response rates of 58% when given in combination with
5-FU and folinic acid irrespective of the patients' pre-
vious treatment status [6].
Patients and methods
Patients (Table 1)
Each patient was required to have a previously diagnosed colorectal
carcinoma with metastases that could be measured by CT scan. For
inclusion, patients had to have confirmed tumor progression when
they had been treated with a fluoropyrimidine-containing regimen.
Patients with any of the following conditions were not eligible for
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Table 1. Patient characteristics.
Characteristic No. of patients (%)
Study I Study H
No. of patients entered 58 51
Age range, years
39-50 6 (10) 9 (18)
51-60 19 (33) 15 (29)
61-75 33 (57) 27 (53)
Sex
Male 36 (62) 32 (63)
Female 22 (38) 19 (37)
Site of primary tumor
Colon 38 (66) 28 (55)
Rectum 20 (34) 23 (45)
ECOG performance status
0-1 50 (86) 46 (90)
2 7 (12) 5 (10)
3 1 (2)
Sites of metastatic tumor involvement
Liver only 30 (52) 20 (39)
Liver and other sites1 18(31) 20(39)
Other sites" 10(17) 11(22)
Number of sites of tumor involvement
1 40 (69) 31 (61)
2 17 (29) 17 (33)
3 1 (2) 3 (6)
Previous dose of 5-FU in g/m2 c
<30 21(36) 34(67)
31-60 19(33) 15(29)
>60 18 (31) 2 (4)
No. of prior regimens of chemotherapy11
1 24 (41) 39 (76)
2 33 (57) 9 (18)
3 1 (2) 3 (6)
* Including lung, adrenals, lymph nodes, bone, ovaries, perito-
neum, pelvis, and spleen.
b
 Including lymph nodes, pelvis, and peritoneum.
c
 Median doses of 5-FU given to patients prior to their enrolment
in study I and study II were 40 g/m2 (range, 6-134 g/m2) and 23
g/m2 (range, 5-76 g/m2), respectively.
d
 Previous fluoropyrimidine-containing regimens comprised 5-FU
and folinic acid (FA), and 5-FU with FA combined with hydroxy-
urea, a-interferon, mitomycin C, lomustine, methotrexate, pyra-
rubicine, or etoposide, and ftorafur as a single agent.
the studies: CNS metastases, bone metastases, or serosal effusions as
the sole indicator of tumor; any prior cisplatin- or paraplatin-con-
taining chemotherapy, performance status (ECOG) >2, a serum
alkaline phosphatase or bilirubin level above twice the upper limit of
the normal range, or creatinine clearance <60 ml/min. Written
informed consent was obtained, and administrative requirements
were met.
Two phase II studies were performed consecutively. Fifty-eight
patients were included in study I. Of these, three had tumors that
could not be measured. After completion of study I, we started a
second trial (study n), which accrued 51 patients, all of them evalu-
able for response to therapy. The 109 patients enrolled in studies I
and II were evaluated for toxic effects. Studies I and II were con-
ducted by different groups of investigators.
Treatment protocol
Therapy consisted of a single i.v. infusion of L-OHP at a dose of 130
mg/m2, repeated every 21 days. The dose of the drug was chosen on
the basis of recommendations of the published phase I studies [2, 5].
L-OHP (Debiopharm SA., Lausanne, Switzerland) was provided as
a lyophilised powder. It was reconstituted in a solution of 5% dex-
trose in water at a final concentration of L-OHP of 2 mg/ml. The
solution was infused i.v. over 2 hours. Patients received no pre-
hydration. The dose of L-OHP was reduced by 25% in instances of
WHO grade 3 granulocytopenia or thrombocytopenia, or of grade 3
peripheral neuropathy according to the scale in Table 2. A single
grade 4 episode of any of these toxic effects led to discontinuation of
the treatment. All patients were given antiemetics.
Patient evaluation
Before each treatment course, patients underwent a clinical exam-
ination and blood cell counts, liver function tests and determina-
tions of serum creatinine. Patients were monitored for antitumor
response after sets of 3 consecutive courses. Plasma CEA and CA
19-9 levels were measured in all patients. Response was determined
quantitatively by comparison of the size of all measurable lesions,
as evidenced on CT scan. Objective responses were categorized
according to the WHO criteria. Response to therapy was deter-
mined initially by the radiologist and the patient's clinician, and by a
second-party review for final evaluation. The times to disease pro-
gression were calculated from the date of initiation of therapy. Sur-
vival analysis and plotting of cumulative probability of the incidence
of neuropathy according to dose were performed by the method of
Kaplan and Meier.
Results
Toxic effects
Study I. The 58 patients received a total of 314 courses
of L-OHP (range, 1-16 courses per patient; median, 5
courses) which were evaluated for toxicity (Table 2).
The median cumulative dose of L -OHP given to pa-
tients during study I was 650 mg/m2 (range, 130-1990
mg/m2).
Table 2. Toxic effects.
Toxic effect
Diarrhea'
Nausea/vomiting'
Granulocytopenia*
Anemia*
Thrombocytopenia*
Peripheral neuro-
pathy1"
Increase in serum
creatinine*
Study
I
U
I
n
i
ii
i
ii
i
II
i
n
i
II
Percent of patients with
Grade
0
55
70
26
40
89
94
65
74
77
88
2
4
95
100
Grade
1
21
11
34
22
5
6
27
19
9
8
28
37
5 d
-
Grade
2
14
19
23
30
4
-
6
5
14
4
39
41
-
-
tenacity0
Grade
3
10
-
17
6
2
-
2
2
-
-
23
14
-
-
Grade
4
_
-
-
2
-
-
-
-
-
-
8
4
-
-
* Graded according to WHO.
b
 Grade 1: dysesthesia and/or paresthesia, transient, <7 days; grade 2: dys-
esthesia and/or paresthesia, transient, < 14 days; grade 3: dysesthesia and/or
paresthesia persisting during the drug-free interval between courses; grade 4:
severe dysesthesia and/or hypoesthesia with functional impairment.
c
 Fifty-eight patients were assessed for tenacity in study I, and 51 patients in
study II. For patients who had >2 episodes of the same toxic effect, only the
highest grade of toxicity is reported in the table.
d
 Single episodes of transient increase to < l j x the upper limit of the normal
range.
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Diarrhea was a toxic effect in 45% of the patients;
10% of them had grade 3 diarrhea, and grade 3 vom-
iting was observed in 17%. Myelosuppression was mild.
Transient increase in the serum creatinine level to
<1.5x the upper limit of the normal range was ob-
served in 5% of the patients.
Sensory peripheral neuropathy was observed in
98% of the patients. Grades were 1 in 28%, 2 in 39%, 3
in 23%, and 4 in 8% of the patients. The incidence and
severity of the peripheral neuropathy rose with increas-
ing cumulative doses of L-OHP. A correlation was
found between the increasing grades of the neuropathy
and the total amounts of the drug given to patients
(Spearman Correlation Test, p < 0.00001). At cumula-
tive doses of <780 mg/m2 of L-OHP, grades 3 and 4
peripheral neuropathy were observed in 14% and 4%
of patients, respectively. The projected probability for
patients to have neuropathy of grades 3 or 4 after they
received cumulative L -OHP doses of 780 mg/m2 was
22%. A number of patients had long-term neurologic
follow-up after discontinuation of L-OHP. Of the 13
patients who had grade 3 neuropathy, 5 had disappear-
ance of all symptoms at between 2 and 4 months, 2
patients had major attenuation after 2-5 months, and 6
patients had no long-term follow-up. Of the 5 patients
who had grade 4 neuropathy, 1 had disappearance of
symptoms after 2 months, 2 had partial regression at 3
and 5 months, and 2 had no long-term follow-up. Dur-
ing the infusion time of L-OHP, one patient had a tran-
sient episode of dyspnea sine materia of unknown
cause.
Study II. The 51 patients received 203 courses of L-
OHP (range, 2-8 courses per patient, median, 3
courses) which were evaluated for toxicity (Table 2).
The median cumulative dose of oxaliplatin given to pa-
tients during study II was 390 mg/m2 (range, 260-1010
mg/m2).
Thirty percent of patients had grades 1 or 2 diar-
rhea. Grades 3 or 4 vomiting was observed in 8% of
patients. Myeloid toxicity was mild.
Sensory peripheral neuropathy was noted in 96% of
the patients. Grades were 1 in 37%, 2 in 41%, 3 in
14%, and 4 in 4% of patients. As in study I, the inci-
dence and severity of the peripheral neuropathy rose
with increasing cumulative doses of L-OHP. A correla-
tion was found between increasing grades of the neuro-
pathy and the total dose of the drug administered to
patients (Spearman Correlation Test, p - 0.0001). Of
the 9 patients who had grades 3 and 4 neuropathy, 2
had disappearance of all symptoms and 7 had attenua-
tion of symptoms at between 3 and 6 months after dis-
continuation of L-OHP. However, follow-up was too
short for precise evaluation of the regression potential
of the neuropathy.
Response to therapy
Study I. The median follow-up time for the 55 evalu-
able patients was 7 months (range, 1-18.5 months). Six
patients attained a PR The response rate was 11%
(95% Q , 0.03-0.19). Times to disease progression in
responders were 5, 5, 6, 6, 6+, and 13 months. The
time required for achievement of response was 6 weeks
in all patients. The median survival time of the 58
patients was 8.2 months. Survival times of the respond-
ers were 9, 9+, 12,14.5,15, and 18.5 months. Twenty-
three patients (42%) had NC, and 26 patients (47%)
had PD.
Study II. The median follow-up time for the 51 pa-
tients was 4.5 months (range, 1-13 months). Five
patients attained a PR The response rate was 10%
(95% CI, 0.017-0.18). Times to disease progression in
responders were 4, 4, 4.5+, 6, and 9 months. The time
required for achievement of response was 6 weeks in 4
patients and 12 weeks in 1 patient. Survival times of
responders were 4+, 5.5, 6+, 7+, and 12 months. Six-
teen patients (31%) had NC, and 30 patients (59%)
had PD.
The overall response rate for the 106 evaluable
patients treated in the 2 trials was 10% (95% CI, 0.046-
0.16). For patients who attained a PR, ratios of initial
CEA titer/final CEA liter (in ng/ml) were 2558/19,
77/7,161/38,610/153,453/291, and 25/11 in study I,
and 185/7, 230/22, 35/8, 3000/1000, and 23/8 in
study II; ratios of initial CA 19-9 titer/final CA 19-9
titer (in units/ml) were 628/32, 2700/380, 106/50,
76/42, 21/15, and 370/380 in study I, and 294/24,
220/24,900/388,270/140, and 67/39 in study H.
Discussion
Cisplatin (CDDP) and paraplatin (CBDCA) have failed
in the past to demonstrate significant antitumor activity
in patients with colorectal carcinoma. When they were
administered as single agents, these drugs yielded re-
sponse rates of 0% to 9% for CDDP [7, 8] and 0%
to 5% for CBDCA [9]. In these studies, the mean
response rates achieved by patients who had previously
received chemotherapy were 3% and 2% for CDDP
and CBDCA, respectively. Moreover, combination
treatment with 5-FU and cisplatin did not produce a
greater response rate than that observed with 5-FU
given as a single agent [10].
In the present phase II trials with oxaliplatin, re-
sponse rates were 11% and 10% in study I and study n,
respectively. These apparently modest results compare
favorably with those obtained with CDDP and
CBDCA [7-9], and they may indicate a significant
therapeutic activity of L-OHP because they were ob-
tained in patients with tumors who had demonstrated
PD during prior therapy including the use of fluoro-
pyrimidines (Table 1).
The dose-limiting toxic effect of oxaliplatin was sen-
sory peripheral neuropathy, which occurred in almost
all of the patients. The major symptom was dysesthesia,
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which predominated in the limbs and the mucosae of
the upper aerodigestive tract; it was often triggered by
exposure to cold temperatures. The incidence and
severity of the peripheral neuropathy rose with increas-
ing cumulative amounts of L-OHP. The projected prob-
ability for patients to have neuropathy of grades 3 or 4
after receiving a cumulative dose of 780 mg/m2 (i.e.,
the amount of drug given in 6 courses of therapy) was
22%. Despite its high incidence, the severe neuropathy
had a favorable course after discontinuation of oxali-
platin in patients who underwent a long-term neuro-
logic assessment during their follow-up. Therefore,
neuropathy should be considered to be within accept-
able limits of tolerance at the dose and schedule of
L - O H P used in the present study. However, we recom-
mend cessation of treatment if neuropathy of grades
> 3 appears.
Oxaliplatin has major similarities with tetraplatin
[tetracMoro(D,L-trans)l,2-diaminocyclohexane platinum
(TV)], a platinum complex which, like L-OHP, has a
(dach) carrier ligand [3]. However, early clinical studies
of tetraplatin have shown that this drug, unlike oxali-
platin, produced severe toxic effects which have pre-
vented its further development. The better toxicity
profile of oxaliplatin over that reported for tetraplatin
further supports the future development of L -OHP for
clinical use.
Preclinical data on L -OHP included a possible
potentiation of 5-FU [2]. Therapy with 5-FU, folinic
acid, and oxaliplatin given at a circadian rhythm-modu-
lated infusion rate produced high response rates in
patients with advanced colorectal carcinoma, which
suggests that potentiation may occur in this tumor as
weU [6].
In the present studies, we have demonstrated that
oxaliplatin possesses modest, but definite activity in
patients with advanced colorectal carcinoma who were
previously resistant to chemotherapy which included
fluoropyrimidines. The data reported here will serve as
a basis for future studies of L -OHP in various doses and
schedules, in combination with 5-FU and folinic acid,
for determination of the therapeutic potential of the
drug.
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